EXPRESSION OF RAS ONCOGENE P21 PROTEIN IN ESOPHAGEAL SQUAMOUS-CELL CARCINOMA

被引:17
作者
RUOL, A
STEPHENS, JK
MICHELASSI, F
SEGALIN, A
CHIARELLI, S
PERACCHIA, A
SKINNER, DB
LITTLE, AG
机构
[1] UNIV PADUA,DEPT SURG 1,I-35100 PADUA,ITALY
[2] UNIV PADUA,DEPT PATHOL,I-35100 PADUA,ITALY
[3] UNIV CHICAGO,MED CTR,DEPT SURG,CHICAGO,IL 60637
[4] UNIV CHICAGO,MED CTR,DEPT PATHOL,CHICAGO,IL 60637
关键词
monoclonal antibody RAP‐5; Prognosis; TNM staging system;
D O I
10.1002/jso.2930440304
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to investigate the value of ras oncogene expression as a prognostic indicator in esophageal squamous cell carcinoma, we evaluated the level of ras oncogene protein product (p21) in 52 specimens resected between 1977 and 1986. All patients were followed until death or for at least 2 years. Pathology slides and archival paraffin blocks were retrieved for confirmation of the original diagnosis, study of histopathologic features, and measurement of p21 content. P21 titers were obtained using the RAP‐5 monoclonal antibody in a semiquantitative immunohistochemical assay. Titer was expressed as the highest dilution of antibody giving definitive staining using the avidin‐biotin peroxidase method. Ras oncpgene was expressed in 88.5% of the specimens. We did not find a significant correlation between ras expression and any of a variety of clinical and histopathologic prognostic parameters. Although patients' median survival after resection of specimens with ras oncogene expression was less than half the median survival after removal of tumors without such expression, this difference was not statistically significant. Further prospective investigations are needed to assess the role of ras oncogene evaluation in clinical practice. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:142 / 145
页数:4
相关论文
共 27 条
[1]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[2]   VIRAL ONCOGENES [J].
BISHOP, JM .
CELL, 1985, 42 (01) :23-38
[3]  
BUICK RN, 1984, CANCER RES, V44, P4909
[4]  
CZERNIAK B, 1989, CANCER, V63, P2008, DOI 10.1002/1097-0142(19890515)63:10<2008::AID-CNCR2820631024>3.0.CO
[5]  
2-D
[6]  
CZERNIAK B, 1987, CANCER, V60, P2432, DOI 10.1002/1097-0142(19871115)60:10<2432::AID-CNCR2820601014>3.0.CO
[7]  
2-1
[8]   ACTIVATED PROTO-ONC GENES - SUFFICIENT OR NECESSARY FOR CANCER [J].
DUESBERG, PH .
SCIENCE, 1985, 228 (4700) :669-677
[9]   RAS P21 EXPRESSION IN THE PROGRESSION OF BREAST-CANCER [J].
FROMOWITZ, FB ;
VIOLA, MV ;
CHAO, S ;
ORAVEZ, S ;
MISHRIKI, Y ;
FINKEL, G ;
GRIMSON, R ;
LUNDY, J .
HUMAN PATHOLOGY, 1987, 18 (12) :1268-1275
[10]   INTRINSIC GTPASE ACTIVITY DISTINGUISHES NORMAL AND ONCOGENIC RAS-P21 MOLECULES [J].
GIBBS, JB ;
SIGAL, IS ;
POE, M ;
SCOLNICK, EM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (18) :5704-5708